There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL – Research Report), Cyclo Therapeutics (CYTH – Research Report) and Xoma (XOMA – Research Report) with bullish sentiments.
Exelixis (EXEL)
In a report released today, Kaveri Pohlman from BTIG reiterated a Buy rating on Exelixis, with a price target of $27.00. The company’s shares closed last Tuesday at $23.46, close to its 52-week high of $24.34.
According to TipRanks.com, Pohlman is a 4-star analyst with an average return of
Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $26.53, an 11.9% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
Cyclo Therapeutics (CYTH)
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Cyclo Therapeutics today and set a price target of $3.00. The company’s shares closed last Tuesday at $1.46.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of
Currently, the analyst consensus on Cyclo Therapeutics is a Strong Buy with an average price target of $3.20, which is a 120.7% upside from current levels. In a report issued on April 22, Ascendiant also initiated coverage with a Buy rating on the stock with a $2.60 price target.
Xoma (XOMA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma, with a price target of $74.00. The company’s shares closed last Tuesday at $25.34, close to its 52-week high of $27.00.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xoma with a $57.00 average price target, which is an 119.9% upside from current levels. In a report issued on April 29, Leerink Partners also initiated coverage with a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXEL:
